

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

10/553,906

Thomas Bergman et al.

October 21, 2005

Title

Filed

HUMAN ALKALINE SPHINGOMYELINASE

AND USE THEREOF

Docket No.

41348

Customer No.:

000116

Mail Stop Missing Parts **Commissioner for Patent** P.O. Box 1450 Alexandria, VA 22313-1450

LETTER RESPSONDING TO THE NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, dated September 5, 2006, applicant encloses an electronic form of the Sequence Listing, which the sequence listing information recorded in computer readable form is identical to the enclosed written paper and where applicable, includes no new matter, as required by 37 CFR 1.821 (e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

The two month period for response expired on November 5, 2006. Accordingly, applicant respectfully requests and petitions that the response date be extended for one month, up to and including December 5, 2006. The \$120.00 extension of time fee is enclose.

Please note the different sequences:

SEQ ID NO 1	protein from human intestine
SEQ ID NO 2	nucleotide sequence for protein from human intestine
SEQ ID NO 3	protein from human intestine
SEQ ID NO 4	protein from human intestine
SEQ ID NO 5	nucleotide sequence for protein from human intestine
SEQ ID NO 6	protein from human intestine

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Ronald M. Kachmarik

Signature of Attorney

November 7, 2006

Date

Appl. No.: 10/553,908

Response filed November 7, 2006

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures

SEQ ID NO 7	protein from human intestine
SEQ ID NO 8	protein from human intestine
SEQ ID NO 9	protein from human intestine
SEQ ID NO 10	artificial DNA corresponds to expressed tag
SEQ ID NO 11	artificial DNA corresponds to expressed tag
SEQ ID NO 12	artificial DNA primer
SEQ ID NO 13	artificial DNA primer .
SEQ ID NO 14	artificial DNA primer
SEQ ID NO 15	artificial DNA primer
SEQ ID NO 16	human protein .
SEQ ID NO 17	artificial DNA primer
SEQ ID NO 18	artificial DNA primer

We have therefore inserted "Human" in figure 223 for the sequences 1-9 and 16, and "Artificial" for the sequences 10-15 and 17-18.

Regarding sequence 5 there is an explanation of "n", which has been corrected from position 905 to position 965. It is clear that the "n" is situated in position 965 from the sequence as such.

If there are any fees required by this communication, please charge such fees to our Deposit Account No.: 16-0820, Order No.: 41348.

Respectfully submitted,

PEARNE & GORDON LLP-

Ronald M. Kachmarik, Reg. No. 34512

1801 East 9th Street Suite 1200 Cleveland, Ohio 44114-3108 216-579-1700 November 7, 2006 The state of the s

26288

STOCKHOLM.

SWEDEN

UNITED STATES AND TRADEMARK OFFICE

NOV 1 3 2006-

UNITED STATES DISPARTMENT OF COMMERCE United States Patent and Trademark Uffice Address COMMISSIONER FOR PATENTS

Alacondos, Vanish 22313-1454

U.S. APPLICATION NUMBER NO.

SE-114 85 STOCKHOLM; SWEDENn

FIRST NAMED APPLICANT

ATTY DOCKBT NO.

Tomas Bergman

71752-81710

PCT/SE04/00628

I.A. FILING DATE

PRIORITY DATE

04/23/2004

04/24/2003

CONFIRMATION NO. 1877
371 FORMALITIES LETTER
IN THE PROPERTY OF THE PROPERTY O

OC000000020298838*

Date Mailed: 09/05/2006

ALBIHNS STOCKHOLM AB

BOX 5581, LINNEGATAN 2

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-8845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

11/14/2006 YPOLITE1 80000010 11553906

LAMONT M HUNTER: 1251

120.89 UP

Telephone: (703) 308-9140 EXT 201

Adjustment date: 11/30/2006 SSANDAR1 11/14/2006 YPOLITE1 00000010 11553906 01 FC:1251 -120.00 OP